Renaissance Technologies’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-12,756
| Closed | -$145K | – | 4234 |
|
|
2023
Q4 | $145K | Sell |
12,756
-12,100
| -49% | -$95.1K | ﹤0.01% | 3221 |
|
|
2023
Q3 | $100K | Buy |
24,856
+3,496
| +16% | +$25.9K | ﹤0.01% | 3248 |
|
|
2023
Q2 | $152K | Buy |
21,360
+1,718
| +9% | +$11.9K | ﹤0.01% | 3357 |
|
|
2023
Q1 | $146K | Sell |
19,642
-13,655
| -41% | -$115K | ﹤0.01% | 3379 |
|
|
2022
Q4 | $242K | Sell |
33,297
-14,807
| -31% | -$125K | ﹤0.01% | 3332 |
|
|
2022
Q3 | $467K | Buy |
48,104
+16,368
| +52% | +$306K | ﹤0.01% | 2965 |
|
|
2022
Q2 | $606K | Buy |
31,736
+10,616
| +50% | +$275K | ﹤0.01% | 3043 |
|
|
2022
Q1 | $1.05M | Buy |
21,120
+15,960
| +309% | +$827K | ﹤0.01% | 2695 |
|
|
2021
Q4 | $390K | Sell |
5,160
-34,919
| -87% | -$2.38M | ﹤0.01% | 3206 |
|
|
2021
Q3 | $3.17M | Buy |
+40,079
| New | +$4.03M | ﹤0.01% | 1746 |
|
|
2020
Q4 | – | Sell |
-10,990
| Closed | -$1.87M | – | 3811 |
|
|
2020
Q3 | $1.87M | Sell |
10,990
-10
| -0.1% | -$1.44K | ﹤0.01% | 2176 |
|
|
2020
Q2 | $1.83M | Sell |
11,000
-360
| -3% | -$56.2K | ﹤0.01% | 2236 |
|
|
2020
Q1 | $1.32M | Buy |
11,360
+170
| +2% | +$23.9K | ﹤0.01% | 2281 |
|
|
2019
Q4 | $1.66M | Buy |
11,190
+8,450
| +308% | +$1.28M | ﹤0.01% | 2410 |
|
|
2019
Q3 | $374K | Buy |
+2,740
| New | +$385K | ﹤0.01% | 2966 |
|
Renaissance Technologies's HARP Position: Q1 2024 in Review
Renaissance Technologies sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q1 2024, closing a stake of 12,756 shares — an estimated $145K sold.
Renaissance Technologies first reported a position in HARP in Q3 2019 and held it in 15 quarters. The position peaked at $3.17M in Q3 2021. 0 funds tracked by Wall St. Rank hold HARP as of Q1 2024.
- Renaissance Technologies reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Renaissance Technologies sold 12,756 Harpoon Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $145K.
- Renaissance Technologies first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q3 2019 and held it in 15 quarters.
- Renaissance Technologies's Harpoon Therapeutics, Inc. Common Stock position peaked at $3.17M in Q3 2021.
- 0 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Renaissance Technologies's 13F filing for Q1 2024, filed 13 May 2024.